41918
document
Double-blind placebo-controlled trial of pentoxifylline added to risperidone : effects on aberrant behavior in children with autism . BACKGROUND There are several lines of evidence to indicate that the immune system plays an important role in the pathophysiology of autism . The objective of this study was to access the effects of pentoxifylline plus risperidone in the treatment of autistic disorder . METHODS Forty children between the ages 4 and 12 years with a DSM IV-TR clinical diagnosis of autism were recruited . The children presented with a chief complaint of severely disruptive symptoms related to autistic disorder . Patients were randomly allocated to pentoxifylline+risperidone or placebo+risperidone for a 10-week , double-blind , placebo-controlled study . The dose of risperidone was titrated up to 3 mg/day , pentoxifylline was titrated to 600 mg/day . Patients were assessed at baseline and after 2 , 4 , 6 , 8 and 10 weeks of starting medication . The measure of the outcome was the Aberrant Behavior Checklist-Community ( ABC-C ) . RESULTS The difference between the two protocols was significant as the group that received pentoxifylline had greater reduction in ABC-C subscale scores for Irritability , Lethargy/Social Withdrawal , Stereotypic Behavior , Hyperactivity/Noncompliance and Inappropriate Speech . CONCLUSION The results suggest that combination of atypical antipsychotic medications and pentoxifylline might have synergistic effects in treatment of behavioral problems of children with autism .
41919
Intervention_Pharmacological
pentoxifylline added to risperidone
41920
Intervention_Pharmacological
pentoxifylline plus risperidone
41921
Intervention_Pharmacological
pentoxifylline+risperidone
41922
Intervention_Pharmacological
placebo+risperidone
41923
Intervention_Pharmacological
risperidone
41924
Intervention_Pharmacological
pentoxifylline
41925
Intervention_Pharmacological
pentoxifylline
41926
Intervention_Pharmacological
combination of atypical antipsychotic medications and pentoxifylline
41927
Outcome_Mental
aberrant behavior in children with autism
41928
Outcome_Mental
treatment of autistic disorder
41929
Outcome_Mental
Aberrant Behavior Checklist-Community ( ABC-C ) .
41930
Outcome_Mental
ABC-C subscale scores for Irritability , Lethargy/Social Withdrawal , Stereotypic Behavior , Hyperactivity/Noncompliance and Inappropriate Speech
41931
Outcome_Mental
behavioral problems of children with autism
41932
Participant_Age
children
41933
Participant_Condition
autism
41934
Participant_Sample-size
Forty
41935
Participant_Age
children
41936
Participant_Age
ages 4 and 12 years
41937
Participant_Condition
autism
41938
Participant_Age
children
41939
Participant_Condition
autistic disorder
41940
Participant_Age
children
41941
Participant_Condition
autism